The three stocks we are going to discuss today come from one of the hottest sectors.
This sector has made headlines since April as the coronavirus came into focus outside of China.
Now, the biotech sector is all the rage as companies scramble to find a suitable vaccine. Investors are searching for the vaccine stock that will beat all the others.
The S&P Biotech SPDR ETF (NYSE: XBI) — an exchange-traded fund (ETF) tracking some of the biggest biotech stocks — jumped more than 79% since reaching a low in March 2020.
It topped out at around $120 per share in July and has only pulled back slightly since.
The ETF holds companies like Sorrento Therapeutics Inc. (Nasdaq: SRNE), OPKO Health Inc. (Nasdaq: OPK) and Moderna Inc. (Nasdaq: MRNA). All of these companies could be classified as COVID-19 vaccine stocks.
It also includes one stock that Chief Investment Strategist Adam O’Dell recommended to his Green Zone Fortunes readers in May that’s up more than 100%.
Biotech ETF Jumps 79%
Which Vaccine Stock Is a Buy?
In this episode of The Bull & The Bear, I’ll talk with Adam and contributor Charles Sizemore about three biotech stocks.
We’ll examine what each of these three companies do and how they’ve performed recently.
What’s even better is you’ll get insight on what you should do with these three companies — if you are thinking about buying or already have them in your portfolio.
Remember, knowing the data and the details about a specific company helps you determine whether it is worth investing in.
That’s why we do the work for you by looking at these specific stocks and give our analysis on each one.
The Bull & The Bear
Led by Adam and a team of finance journalists, traders and experts, Money & Markets gives you the information you need to protect your nest egg, grow your wealth and safeguard your financial well-being.
Be sure to also subscribe to our YouTube channel for more videos and information.
Have something you want us to talk about? Email us at firstname.lastname@example.org and give us your thoughts.
Check out moneyandmarkets.com and sign up for our free newsletters that deliver you the most important and unbiased financial news, commentary and actionable advice.
Also, follow us on:
Research Analyst, Money & Markets
Matt Clark is the research analyst for Money & Markets. He’s the host of our podcast, The Bull & The Bear, as well as the Marijuana Market Update. Before joining the team, he spent 25 years as an investigative journalist and editor — covering everything from politics to business.